Clinical Trials Logo

Plasmodium Berghei clinical trials

View clinical trials related to Plasmodium Berghei.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03138096 Completed - Malaria,Falciparum Clinical Trials

Safety and Protective Efficacy of Pb(PfCS@UIS4)

PbVac
Start date: May 29, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

In the underlying study, a genetically modified P. berghei parasite is used. P. berghei is one of the four Plasmodium species that causes malaria in rodents. The hypothesis is that immunization of humans with P. berghei will induce a cross-species immune response without the risk of a breakthrough infection. To further increase the potential for protective efficacy, the P. falciparum circumsporozoite (CS)- protein gene has been integrated in the P. berghei parasite, generating a genetically modified P. berghei parasite, abbreviated as Pb(PfCS@UIS4).